CJC-1295 / Ipamorelin

CJC-1295 and Ipamorelin are two investigational peptides frequently combined and marketed for growth hormone (GH) release. This combination is not an FDA-approved drug but is often compounded, raising significant safety and regulatory concerns. The FDA has explicitly flagged these substances due to a lack of adequate human safety data and potential risks.

Overview of CJC-1295 and Ipamorelin

CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), a naturally occurring peptide that stimulates the pituitary gland to release GH. It is a 29-amino-acid peptide, distinct from CJC-1295 with Drug Affinity Complex (DAC), which is considered a different active moiety. CJC-1295 is not a native human peptide but a modified analog designed to mimic GHRH's function.

Ipamorelin is a synthetic Growth Hormone Releasing Peptide (GHRP). It acts as a selective agonist of the ghrelin/GHS pathway, stimulating GH release with strong selectivity, meaning it has minimal impact on the release of other hormones like ACTH or cortisol.

When combined, CJC-1295 and Ipamorelin are intended to synergistically stimulate the body's natural production and release of growth hormone. This combination is often promoted for various off-label uses, including anti-aging, muscle growth, and fat loss.

Regulatory and Safety Concerns

Crucially, neither CJC-1295 nor Ipamorelin, nor their combination, has received FDA approval as a drug. They are considered investigational substances. The FDA has raised explicit concerns regarding peptides like CJC-1295 and Ipamorelin when used in compounding pharmacies or sold in the "gray market." These concerns include:

• Lack of adequate human safety data: There is insufficient evidence to establish their safety profile in humans.
• Immunogenicity: The potential for the body to develop an immune response to these synthetic peptides.
• Peptide-related impurities: Issues with the purity of the compounded substances.
• Characterization complexity: Difficulties in accurately identifying and quantifying the active components.
• Serious adverse events: The potential for severe negative health outcomes.

The FDA distinguishes these substances from legitimate, FDA-approved GH-axis peptides like Tesamorelin, which has undergone rigorous clinical trials and demonstrated efficacy and safety for specific indications. The agency has issued warning letters and listed CJC-1295 and Ipamorelin among bulk drug substances that may present significant safety risks when used in compounding.

Current Status

CJC-1295 and Ipamorelin remain investigational and are not approved for any medical indication. Their use, particularly in compounded forms, is subject to significant regulatory scrutiny and carries substantial safety risks due to the lack of comprehensive clinical data and potential manufacturing quality issues.